UROGEN PHARMA Revenue 2016-2021 | URGN

UROGEN PHARMA revenue from 2016 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
UROGEN PHARMA Annual Revenue
(Millions of US $)
2020 $12
2019 $0
2018 $1
2017 $8
2016 $18
2015 $
UROGEN PHARMA Quarterly Revenue
(Millions of US $)
2021-06-30 $13
2021-03-31 $7
2020-12-31 $8
2020-09-30 $3
2020-06-30 $0
2020-03-31
2019-12-31
2019-09-30
2019-06-30 $0
2019-03-31
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $8
2017-06-30
2017-03-31 $0
2016-12-31
2016-09-30
2016-06-30
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.012B
UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29